TD Asset Management Inc. purchased a new position in shares of HeartWare International Inc. (NASDAQ:HTWR) during the second quarter, Holdings Channel reports. The institutional investor purchased 4,100 shares of the company’s stock, valued at approximately $237,000.

A number of other institutional investors have also made changes to their positions in the stock. UBS Asset Management Americas Inc. increased its position in shares of HeartWare International by 20.6% in the first quarter. UBS Asset Management Americas Inc. now owns 818,221 shares of the company’s stock worth $25,707,000 after buying an additional 139,737 shares during the period. Franklin Resources Inc. increased its position in shares of HeartWare International by 1.9% in the first quarter. Franklin Resources Inc. now owns 579,967 shares of the company’s stock worth $18,222,000 after buying an additional 11,036 shares during the period. Bogle Investment Management L P DE increased its position in shares of HeartWare International by 71.5% in the first quarter. Bogle Investment Management L P DE now owns 310,078 shares of the company’s stock worth $9,742,000 after buying an additional 129,326 shares during the period. State Street Corp increased its position in shares of HeartWare International by 1.3% in the first quarter. State Street Corp now owns 301,629 shares of the company’s stock worth $9,471,000 after buying an additional 3,740 shares during the period. Finally, Chicago Capital Management LLC acquired a new position in shares of HeartWare International during the second quarter worth about $16,176,000.

HeartWare International Inc. (NASDAQ:HTWR) remained flat at $57.98 on Monday. The firm has a 50 day moving average price of $57.82 and a 200-day moving average price of $39.18. HeartWare International Inc. has a 52-week low of $25.02 and a 52-week high of $87.38.

HeartWare International (NASDAQ:HTWR) last issued its earnings results on Thursday, July 28th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.39. The firm earned $68.72 million during the quarter, compared to analyst estimates of $57.36 million. HeartWare International’s revenue was down 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.47) EPS. On average, equities analysts expect that HeartWare International Inc. will post ($3.07) EPS for the current fiscal year.

HTWR has been the subject of several research analyst reports. Zacks Investment Research downgraded HeartWare International from a “buy” rating to a “hold” rating in a report on Tuesday, August 16th. Wells Fargo & Co. downgraded HeartWare International from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 29th. Guggenheim initiated coverage on HeartWare International in a report on Wednesday, June 8th. They issued a “neutral” rating for the company. BTIG Research reissued a “hold” rating on shares of HeartWare International in a report on Thursday, August 25th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $66.00 price objective (up from $45.00) on shares of HeartWare International in a report on Monday, June 27th. Fourteen equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $50.00.

In other news, SVP James Schuermann sold 1,000 shares of HeartWare International stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $57.77, for a total value of $57,770.00. Following the completion of the transaction, the senior vice president now owns 12,043 shares in the company, valued at approximately $695,724.11. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Peter F. Mcaree sold 3,125 shares of HeartWare International stock in a transaction that occurred on Monday, July 11th. The stock was sold at an average price of $57.68, for a total value of $180,250.00. Following the completion of the transaction, the chief financial officer now owns 22,130 shares of the company’s stock, valued at approximately $1,276,458.40. The disclosure for this sale can be found here.

HeartWare International Company Profile

Heartware International, Inc is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The Company operates in the segment of design and manufacture of medical devices.

5 Day Chart for NASDAQ:HTWR

Want to see what other hedge funds are holding HTWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HeartWare International Inc. (NASDAQ:HTWR).

Receive News & Ratings for HeartWare International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartWare International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.